-
公开(公告)号：US12226455B2
公开(公告)日：2025-02-18
申请号：US17776749
申请日：2020-11-16
Applicant: RELAXERA Pharmazeutische GmbH & Co. KG
Inventor： Thomas Bernd Dschietzig
Abstract: Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation is described. Also described are methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.
-
公开(公告)号：US12180253B2
公开(公告)日：2024-12-31
申请号：US17900450
申请日：2022-08-31
Applicant: THE TRUSTEES OF INDIANA UNIVERSITY
Inventor： Ronald Mark Payne
Abstract: A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.
-
公开(公告)号：US20240343761A1
公开(公告)日：2024-10-17
申请号：US18744292
申请日：2024-06-14
Applicant: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
Inventor： Philippe SARRET , Pierre-Luc BOUDREAULT , Alexandre MURZA , Kien TRAN , Éric MARSAULT , Jean-Michel LONGPRÉ , Jérôme CÔTÉ
Abstract: Aperlinergic macrocyclic compounds are provided. In particular, a compound of formula (II):
or a stereoisomer or a mixture thereof, or a pharmaceutically acceptable salt, ester or solvate thereof is provided. Also provided is a method of using aperlinergic macrocyclic compounds of the disclosure for treating a cardiovascular disease in a subject in need thereof, comprising administering an effective amount of the compound to the subject.
-
4.发明公开
公开(公告)号：US20230144866A1
公开(公告)日：2023-05-11
申请号：US18054586
申请日：2022-11-11
Inventor： Zhiliang Cheng , Andrew Tsourkas , Ling Qin
CPC classification number: A61K38/446 , A61K9/1273 , A61P39/06 , A61P9/02 , A61P19/02
Abstract: Therapeutic compositions, comprising: an anti-reactive oxygen species agent and a pervious polymersome, the pervious polymersome encapsulating the anti-reactive oxygen species agent, and the pervious polymersome having therein channels defined by a channel diblock copolymer, the channels being arranged so as to retain at least some of the anti-reactive oxygen species agent within the pervious polymersome while allowing reactive oxygen species to pass into the pervious polymersome.
Method of treating a patient, comprising: administering an effective amount of a therapeutic composition, the therapeutic composition comprising an anti-reactive oxygen species agent disposed within a pervious polymersome, the pervious polymersome encapsulating the anti-reactive oxygen species agent, and the pervious polymersome having therein channels defined by a channel diblock copolymer, the channels being arranged so as to retain at least some of the anti-reactive oxygen species agent within the pervious polymersome while allowing reactive oxygen species to pass into the pervious polymersome.
-
公开(公告)号：US20230139956A1
公开(公告)日：2023-05-04
申请号：US17802280
申请日：2021-02-26
Applicant: Talengen International Limited
Inventor： Jinan LI
Abstract: The present application relates to a method for treating abnormal blood pressure condition, which comprises: administrating an effective amount of a component of plasminogen activation pathway to a subject. The present application also relates to a medicament and a product for treating an abnormal blood pressure condition, and use thereof.
-
公开(公告)号：US20220362175A1
公开(公告)日：2022-11-17
申请号：US17872450
申请日：2022-07-25
Applicant: Nevakar Injectables Inc.
Inventor： Tushar Hingorani , Kumaresh Soppimath
IPC: A61K31/137 , A61P9/02 , A61K9/00 , A61K47/12 , A61K47/18
Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
-
公开(公告)号：US20220313773A1
公开(公告)日：2022-10-06
申请号：US17524022
申请日：2021-11-11
Applicant: Amryt Endo, Inc.
Inventor： Gary Patou
IPC: A61K38/095 , A61P1/16 , A61P9/02 , A61P9/12 , A61K9/28 , A61K9/48 , A61K31/573 , A61K45/06
Abstract: Methods are disclosed of treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11446269B2
公开(公告)日：2022-09-20
申请号：US16188905
申请日：2018-11-13
Applicant: Amarin Pharmaceuticals Ireland Limited
Inventor： Richard Preston Mason
IPC: A61K31/202 , A61K31/40 , A61P9/10 , A61P9/02
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing small dense LDL (“sdLDL”) oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
-
公开(公告)号：US11318183B2
公开(公告)日：2022-05-03
申请号：US16981892
申请日：2019-03-15
Applicant: MANKIND PHARMA LTD.
Inventor： Saurabh Kumar , Ankush Gupta , Hanumant Gambhire , Raghuveera H. G , P. V. S Narasimham , Anil Kumar
IPC: A61K38/095 , A61P9/02 , A61K47/12 , A61K47/18
Abstract: The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.
-
公开(公告)号：US11208467B2
公开(公告)日：2021-12-28
申请号：US16642885
申请日：2018-09-06
Applicant: Daiichi Sankyo Company, Limited
Inventor： Daisuke Nishimiya , Masakazu Tamura
IPC: C07K14/81 , A61K35/12 , A61K38/00 , A61K38/48 , A61K47/62 , A61K47/66 , A61K47/68 , A61K48/00 , A61K49/00 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/12 , A61P15/00 , A61P1/02 , A61P1/04 , A61P1/18 , A61P25/18 , A61P25/28 , A61P35/00 , A61P43/00 , A61P9/02 , C07K14/00
Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
